Press Releases Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Market Closed - Nasdaq Other stock markets 03:53:16 2024-06-10 pm EDT			5-day change	1st Jan Change
0.417 ^USD	+1.46%		-12.76%	-35.85%

May. 13	Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 25	Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Salarius: Q1 Earnings Snapshot	May. 13	AQ
Salarius: Q4 Earnings Snapshot	Mar. 22	AQ
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 22	AQ
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	Feb. 22	AQ
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders	Jan. 16	AQ
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment	Jan. 03	AQ
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	Dec. 20	AQ
Salarius: Q3 Earnings Snapshot	Nov. 10	AQ
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program	Nov. 07	AQ
Salarius: Q2 Earnings Snapshot	23-08-10	AQ
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update	23-08-10	AQ
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources	23-08-08	AQ
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients	23-07-11	AQ
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress	23-06-12	AQ
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules	23-05-12	AQ
Salarius: Q1 Earnings Snapshot	23-05-11	AQ
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update	23-05-11	AQ
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma	23-05-09	AQ
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164	23-05-01	AQ
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting	23-04-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Press Releases

Filters